When standard cancer options become limited, where can international patients turn?
China’s landscape for biomarker-driven oncology trials is expanding rapidly. However, the true bottleneck for global patients isn't a lack of medical innovation—it is navigating the complex administrative, linguistic, and institutional barriers required for admission.
As a dedicated medical concierge provider, MedBridgeNZ does not provide medical treatment or clinical advice. Instead, we bridge the logistical gap for patients worldwide by: ✔️ Translating complex pathology and molecular reports ✔️ Screening for trial-specific residency/nationality rules ✔️ Shortlisting operationally reachable trial sites ✔️ Coordinating the complete #MedicalTourismChina pathway
If you are unsure whether your medical records are ready for an international institutional review, our latest guide breaks down exactly what must be confirmed before travel.
Read the full breakdown here: When Standard Cancer Options Become Limited: How International Patients Can Access Biomarker-Driven Oncology Trials in China
